You are here

  • Home
  • Archive
  • Volume 14, Issue 7
  • Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?

Article info

Article menu
Download PDFPDF
Case report
Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?

Authors

  1. Correspondence to Dr Ulrich Moser; u-moser{at}t-online.de
View Full Text

Citation

Moser U
Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?
BMJ Case Reports CP 2021;14:e243072.

Publication history

  • Accepted June 11, 2021
  • First published July 6, 2021.
Online issue publication 
March 05, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.